NASDAQ · NXGLW

NexGel, Inc.

$0.03 -$0.00 (-7.47%) 1D Market open

Key Metrics

$217.89K
Market cap
P/E · TTM
−$156.00K
Revenue · TTM
−$215.00K
Net income
EPS · TTM $-0.03
Dividend yield
Free cash flow
Beta · 1Y -0.35
EBITDA · TTM
Gross margin 81.4%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 8
    The stock moved +114.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 8
  • Jul 7
    From its Feb 3 high, the share price fell 88%.

    Peak close $0.19 on Feb 3; trough close $0.02 on Jul 7. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -88%
  • Feb 6
    The stock moved +69.7% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 6

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value
Shares outstanding
52-wk range$0.02 – $0.35
Avg volume · 20D8.4K
Net cash
Book value / share$0.52
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About NexGel, Inc.
IPO dateDec 17, 2021
Employees19

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 81.4%
Operating 123.7%
Net 137.8%
FCF
ROE / ROIC -4.4% · —

Financial Health

Current ratio1.70
Quick ratio1.02
Debt / equity0.14
Debt / EBITDA
Net cash
Working capital$2.32M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-2.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings